In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target-Reference-Cited by-同舟云学术

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Published:2017-07 Issue:7664 Volume:547 Page:413-418
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Manguso Robert T.,Pope Hans W.,Zimmer Margaret D.,Brown Flavian D.,Yates Kathleen B.,Miller Brian C.,Collins Natalie B.,Bi Kevin,LaFleur Martin W.,Juneja Vikram R.,Weiss Sarah A.,Lo Jennifer,Fisher David E.,Miao Diana,Van Allen Eliezer,Root David E.,Sharpe Arlene H.,Doench John G.,Haining W. Nicholas

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature23270.pdf

Reference35 articles.

1. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016)

2. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013)

3. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016)

4. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002)

5. Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389–1402 (2013)

Cited by 847 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to immunotherapy;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Regulation of protein phosphorylation by PTPN2 and its small-molecule inhibitors/degraders as a potential disease treatment strategy;European Journal of Medicinal Chemistry;2024-11

3. Mechanism of TBK1 activation in cancer cells;Cell Insight;2024-10

4. Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

5. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13